Abstract:Systemic lupus erythematosus (SLE) is a complex autoimmune disease with strong genetic associations within the major histocompatibility complex (MHC) region. Despite significant advances, precisely pinpointing the genetic variants that contribute to SLE risk within the MHC remains challenging. This study aimed to comprehensively profile SLE-driving variants using a newly developed East Asian MHC imputation reference panel, capable of simultaneously imputing diverse MHC variants, including multi-level variants of HLA genes and copy number variations (CNVs) of C4 elements, with high imputation accuracy. Applying this panel to two SLE genome-wide association study datasets, we uncovered the independent contributions from six amino acid positions altering the epitope-binding surfaces of HLA-DRB1 and HLA-C. Additionally, reduced C4A copy numbers and increased HERV copy numbers, collectively lowering C4 protein levels, were associated with increased SLE risk, independent of HLA variants. Our refined MHC-SLE association model provided superior explanations for SLE risk over previous association models. In summary, this study enhanced the understanding of HLA and C4 in SLE pathogenesis and holds promise for advancing MHC association studies for immune-mediated inflammatory disorders in East Asians using our MHC panel (https://coda.nih.go.kr/usab/kis/intro.do). ### Competing Interest Statement SJ is the CEO of both AgingLab and Geromics and an employee of Clinomics. JB is the founder of AgingLab. The other authors declare that they have no conflicts of interest. ### Funding Statement This work was supported by the National Research Foundation (NRF) of Korea [NRF-2021R1A6A1A03038899, NRF-2022R1A2C2092164], the National Facility & Equipment Center [2023R1A6C101A009], the Hanyang University Institute for Rheumatology Research, the U-K BRAND Research Fund [1.200108.01] of UNIST, the Research Project Funded by Ulsan City Research Fund [1.200047.01] of UNIST, and the Ministry of SMEs and Startups (MSS, Korea) [P0016195, P0016193, P0016191; 1425156792, 1425157301, 1425157253; 2.220035.01, 2.220036.01, 2.220037.01]. Further funding was provided by the Korea Planning & Evaluation Institute of Industrial Technology with support from the Ministry of Trade, Industry and Energy in 2024 [RS-2024-00435468, Development and Dissemination of National Standard Technology]. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: IRBs of the Ulsan National Institute of Science and Technology (UNISTIRB-15-19-A, UNISTIRB-16-13-C), Korean Disease Control and Prevention Agency (2022-02-04-P-A, KDCA-2024-02-09-R-01), and Hanyang University (HY-12-005-16, HY-16-07-20, HY-16-129-15) gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data except SLE GWAS datasets produced in the present study are available upon reasonable request to the authors. This individual-level genotype and phenotype data are protected and are not available due to data privacy laws.

Trans-ancestral Studies Fine Map the SLE-susceptibility Locus TNFSF4.

Meta-analysis Followed by Replication Identifies Loci in or Near CDKN1B, TET3, CD80, DRAM1, and ARID5B As Associated with Systemic Lupus Erythematosus in Asians.

Analysis of Trans-Ancestral SLE Risk Loci Identifies Unique Biologic Networks and Drug Targets in African and European Ancestries

A Plausibly Causal Functional Lupus-Associated Risk Variant in the STAT1–STAT4 Locus

Association of TNFSF4 Polymorphisms with Systemic Lupus Erythematosus: a Meta-Analysis.

Defining Mechanistic Links Between the Non-Coding Variant rs17673553 in CLEC16A and Lupus Susceptibility

High-throughput identification of functional regulatory SNPs in systemic lupus erythematosus

Identification of 38 Novel Loci for Systemic Lupus Erythematosus and Genetic Heterogeneity Between Ancestral Groups.

Identification of a New Susceptibility Locus for Systemic Lupus Erythematosus on Chromosome 12 in Individuals of European Ancestry

A Replication Study from Chinese Supports Association Between Lupus-Risk Allele in TNFSF4 and Renal Disorder.

Gene-gene Interaction of BLK, TNFSF4, TRAF1, TNFAIP3, and REL in Systemic Lupus Erythematosus.

Fine-mapping SLE-MHC Associations Revealed Independent Contributions of HLA Missense Variants Andc4copy Number Variations

TNFSF15 is Likely a Susceptibility Gene for Systemic Lupus Erythematosus.

Exome-wide association study identifies four novel loci for systemic lupus erythematosus in Han Chinese population.

Identification of 38 Novel Loci for Systemic Lupus Erythematosus and Genetic Heterogeneity That May Underly Population Disparities in This Disease

Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility

Preferential Association of a Functional Variant in Complement Receptor 2 with Antibodies to Double-Stranded DNA

Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations

Confirmation of Five Novel Susceptibility Loci for Systemic Lupus Erythematosus (SLE) and Integrated Network Analysis of 82 SLE Susceptibility Loci

The genetics of systemic lupus erythematosus and implications for targeted therapy

3 Confirmation of 5 novel susceptibility loci for systemic lupus erythematosus (sle) and integrated network analysis of 82 sle susceptibility loci